AbbVie (NYSE:ABBV) Issues Q2 2025 Earnings Guidance

AbbVie (NYSE:ABBV - Get Free Report) updated its second quarter 2025 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 2.840-2.880 for the period. The company issued revenue guidance of -. AbbVie also updated its FY 2025 guidance to 11.670-11.870 EPS.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Morgan Stanley increased their target price on AbbVie from $241.00 to $250.00 and gave the stock an "overweight" rating in a research report on Monday, April 28th. Erste Group Bank upgraded AbbVie to a "strong-buy" rating in a report on Monday, March 17th. Bank of America raised their price objective on AbbVie to $204.00 and gave the stock a "hold" rating in a report on Monday, June 9th. Evercore ISI raised their price objective on AbbVie from $204.00 to $205.00 and gave the stock an "outperform" rating in a report on Monday, April 28th. Finally, Cantor Fitzgerald began coverage on AbbVie in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $210.00 price objective on the stock. Eight research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $211.29.

AbbVie Stock Up 0.5%

Shares of ABBV stock traded up $0.97 during trading hours on Wednesday, reaching $190.74. The company had a trading volume of 5,593,883 shares, compared to its average volume of 6,289,094. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.64 and a current ratio of 0.76. AbbVie has a twelve month low of $163.81 and a twelve month high of $218.66. The company has a market capitalization of $336.92 billion, a P/E ratio of 81.17, a price-to-earnings-growth ratio of 1.28 and a beta of 0.48. The stock's fifty day simple moving average is $187.10 and its 200 day simple moving average is $188.78.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share for the quarter, beating analysts' consensus estimates of $2.40 by $0.06. AbbVie had a return on equity of 412.03% and a net margin of 7.31%. The firm had revenue of $13.34 billion during the quarter, compared to analyst estimates of $12.91 billion. During the same quarter last year, the firm earned $2.31 EPS. AbbVie's quarterly revenue was up 8.4% on a year-over-year basis. As a group, sell-side analysts expect that AbbVie will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be paid a dividend of $1.64 per share. The ex-dividend date of this dividend is Tuesday, July 15th. This represents a $6.56 dividend on an annualized basis and a yield of 3.44%. AbbVie's dividend payout ratio (DPR) is presently 279.15%.

Institutional Investors Weigh In On AbbVie

An institutional investor recently raised its position in AbbVie stock. Brighton Jones LLC raised its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 17.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 22,912 shares of the company's stock after purchasing an additional 3,401 shares during the quarter. Brighton Jones LLC's holdings in AbbVie were worth $4,072,000 at the end of the most recent quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.